ArticleThe Journal of clinical investigation2017

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

John D Norris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.